Licenses viral vector technology from Penn for CDH17
Filed with ASX · · 3 pages · English
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has expanded its license agreement with the University of Pennsylvania (Penn) related to CDH17 chimeric antigen receptor (CAR) therapies. Under the amended agreement, Chimeric has acquired a non-exclusive know-how license to use Penn’s third-ge
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- A$30 million Equity Placement Agreement with L1 Capital
- Strategic manufacturing partnership with WuXi ATU
- Security Class Reinstatement to Quotation CHMO
- CDH17 CAR t preclinical data featured in Nature Cancer
- Completion of retail component of Entitlement Offer
Later from Chimeric Therapeutics
- Patent received in Japan for CLTX CAR technology
- Exclusive license agreement with CWRU for CORE-NK platform
- Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial
- Follow up period completed for 3rd cohort in CHM 1101 trial
- Chimeric receives $3.06M R&D tax incentive
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics